Article Information
History
- May 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Emily Dema1,#,
- Pam Sonnenberg1,
- Jo Gibbs1,
- Anne Conolly1,2,
- Malachi Willis3,
- Julie Riddell3,
- Raquel Boso Perez3,
- Andrew J. Copas1,
- Clare Tanton4,
- Chris Bonell4,
- Clarissa Oeser1,
- Soazig Clifton1,2,
- Magnus Unemo1,5,
- Catherine H Mercer1,
- Kirstin R Mitchell3,* and
- Nigel Field1,*
- 1Institute for Global Health, University College London, London, UK
- 2NatCen Social Research, London, UK
- 3MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK
- 4Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
- 5Department of Laboratory Medicine, Örebro University, Örebro, Sweden
- ↵#Corresponding author:
Emily Dema, Institute for Global Health, University College London, 3rd floor Mortimer Market Centre, London WC1E 6JB, emily.dema.19{at}ucl.ac.uk
Posted May 01, 2022.
How did the COVID-19 pandemic affect access to condoms, chlamydia and HIV testing, and cervical cancer screening at a population level in Britain? (Natsal-COVID)
